Seller record · Telehealth service

Live Vital

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The terms, the questions, the HIPAA notice, the telehealth consent, the peptide therapy consent and all thirteen treatment pages each stop at a licensed United States compounding pharmacy or a 503A pharmacy. 2 more criteria also fail; see the table below.

At a glance

Live VitalTelehealth service

5/8criteria passed
Price
From $297 for GHK-Cu to $549 for tirzepatide
Sells
semaglutide, tirzepatide, tesamorelin, and 10 more
FDA letters
None on file

Partner link. The site earns a commission on care started through it. Funding

Visit Live VitalSee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling twelve peptides and NAD+ on ten-week protocols, prescribed by one named physician. Its semaglutide and tirzepatide pages are live and priced, and no navigation, footer or index surface on the site links to either of them.

Operating entity Live Vital, LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSLive Vital's FAQ
S2Prescription gatingPASSLive Vital's tirzepatide product page
S3Pharmacy identificationFAILLive Vital's FAQ
S4Compounding disclosureFAILLive Vital's tirzepatide product page
S5Analytical documentationFAILLive Vital's FAQ
S6Business addressPASSLive Vital's terms
S7Price disclosurePASSLive Vital's treatments page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSOne physician is named, with a medical school and a residency, and the site states he reviews every intake before a protocol ships. It draws the line against research use only sellers in its own words and puts itself on the prescribed side of it.Source: Live Vital's FAQ.
S2PASSNo product reaches a cart. The tirzepatide assessment opens on a state-of-residence eligibility question and demands a code sent by text before any payment field, and the medical questions behind that step are not visible without it.Source: Live Vital's tirzepatide product page.
S3FAILNo filling pharmacy is named. The terms, the questions, the HIPAA notice, the telehealth consent, the peptide therapy consent and all thirteen treatment pages each stop at a licensed United States compounding pharmacy or a 503A pharmacy.Source: Live Vital's FAQ.
S4FAILTen of the thirteen treatment pages state that the drug is compounded and not approved by the Food and Drug Administration. The semaglutide, tirzepatide and tesamorelin pages carry neither word, and the first two name the approved brands instead.Source: Live Vital's tirzepatide product page.
S5FAILNo certificate, lot number or purity figure appears anywhere on the site, which publishes no PDF and only five images.Source: Live Vital's FAQ.
S6PASSThe legal pages print a street address on Business Park Drive in Draper, Utah, beside a telephone number, and the site publishes no contact page at all.Source: Live Vital's terms.
S7PASSAll thirteen treatments print a price before intake, from 297 dollars for GHK-Cu to 549 dollars for tirzepatide. The monthly figure beside each total divides it by three while eleven of the thirteen protocols run ten weeks, so the two labels on one card do not describe the same period.Source: Live Vital's treatments page.
S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, tesamorelin, CJC-1295 with ipamorelin, BPC-157, TB-500, GHK-Cu, MOTS-c, glutathione, Glow, Klow, Wolverine, NAD+.

Partner link. The site earns a commission on care started through it. Funding.

Visit Live Vital

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.